Alzamend Neuro Inc. recently issued 243,429 shares of common stock upon the conversion of approximately 564.76 shares of Series B Convertible Preferred Stock. These transactions occurred between July 23 and July 30, 2025, under an exemption from registration requirements as per Section 4(a)(2) of the Securities Act. As of July 30, 2025, the company had a total of 3,139,861 shares of common stock outstanding. The document does not disclose the other party involved in the transaction or the price of the shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-011357), on August 01, 2025, and is solely responsible for the information contained therein.